Huvepharma announced July 2 it has received U.S. Food & Drug Administration approval for CycleGuard 500, a melengestrol acetate feed additive used for suppression of estrus in heifers.
Available as a Type A liquid medicated article, CycleGuard 500 is a bio-equivalent product to MGA from Zoetis and HeiferMaX from Elanco, meaning it provides the same benefits of dosage, chemical identity, potency, quality and safety to the existing melengestrol acetate brands, Huvepharma said in an announcement.
CycleGuard 500 can be used to suppress estrus in heifers intended for breeding as well as to suppress estrus among heifers fed in confinement intended for slaughter, the company said. For feedlot heifers, melengestrol acetate is also proven to increase rate of weight gain and improve feed efficiency. CycleGuard 500 must be mixed with other feeds when fed and be fed according to label directions.
“We are excited to bring more products to the U.S. cattle industry as we continue to rapidly expand our Huvepharma portfolio,” noted Glen Wilkinson, president of Huvepharma U.S. “Huvepharma is focused on offering quality product choices and technical expertise to livestock producers and feeders to aid the industry in enhancing production and efficiency. CycleGuard 500 is one more tool available toward that effort.”
Huvepharma has offered animal health products for cattle, swine and poultry in the U.S. since 2005. In addition to CycleGuard 500, over the past year, the company has received FDA approvals for Monovet 90 (monensin), the first available bio-equivalent monensin, and Optigrid 45 (ractopamine hydrochloride), as well as launched RESPIVax, a new vaccine against bovine respiratory disease.
Huvepharma is a global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. A privately-owned company with U.S. headquarters in Peachtree City, Ga., Huvepharma is based in Sofia, Bulgaria.